Studies have confirmed that blocking PD-1/PD-L1 activates and upregulates the expression of CD8+ T-cells, increases their tumor-killing activity, and induces the expression of major histocompatibility complex molecules on the surface of cancer cells, exposing more cancer cells to immune cells (108). This evidence concerns the gene CD8A and neoplasm.